EPICENTRX

Serial Number 90796010
733

Registration Progress

Application Filed
Jun 25, 2021
Under Examination
Jan 3, 2023
Approved for Publication
Nov 8, 2022
Published for Opposition
Nov 8, 2022
Registered

Trademark Image

EPICENTRX

Basic Information

Serial Number
90796010
Filing Date
June 25, 2021
Published for Opposition
November 8, 2022
Drawing Code
4

Status Summary

Current Status
Active
Status Code
733
Status Date
Jan 4, 2025
Application
Pending
Classes
005 042

Rights Holder

EpicentRx, Inc.

03
Address
11099 North Torrey Pines Road, Suite 160
La Jolla, CA 92037

Ownership History

EpicentRx, Inc.

Original Applicant
03
La Jolla, CA

EpicentRx, Inc.

Owner at Publication
03
La Jolla, CA

Legal Representation

Attorney
Muzamil Huq

USPTO Deadlines

All Deadlines Cleared

All 5 deadline(s) have been cleared by subsequent events. No active deadlines at this time.

Application History

34 events
Date Code Type Description
Jul 1, 2025 EEXT I SOU TEAS EXTENSION RECEIVED
Mar 4, 2025 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jan 4, 2025 EX4G S SOU EXTENSION 4 GRANTED
Jan 4, 2025 EXT4 S SOU EXTENSION 4 FILED
Jan 3, 2025 EEXT I SOU TEAS EXTENSION RECEIVED
Jul 2, 2024 EX3G S SOU EXTENSION 3 GRANTED
Jul 2, 2024 EXT3 S SOU EXTENSION 3 FILED
Jul 2, 2024 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jul 2, 2024 EEXT I SOU TEAS EXTENSION RECEIVED
Jan 5, 2024 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jan 3, 2024 EX2G S SOU EXTENSION 2 GRANTED
Jan 3, 2024 EXT2 S SOU EXTENSION 2 FILED
Jan 3, 2024 EEXT I SOU TEAS EXTENSION RECEIVED
Dec 22, 2023 TCCA I TEAS CHANGE OF CORRESPONDENCE RECEIVED
Dec 22, 2023 ARAA I ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Dec 22, 2023 REAP I TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Jul 5, 2023 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jul 3, 2023 EEXT I SOU TEAS EXTENSION RECEIVED
Jul 3, 2023 EX1G S SOU EXTENSION 1 GRANTED
Jul 3, 2023 EXT1 S SOU EXTENSION 1 FILED
Jan 3, 2023 NOAM E NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Nov 8, 2022 PUBO A PUBLISHED FOR OPPOSITION
Nov 8, 2022 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Oct 19, 2022 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Oct 3, 2022 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER
Sep 23, 2022 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED
Sep 22, 2022 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE
Sep 22, 2022 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED
Mar 22, 2022 CNRT R NON-FINAL ACTION WRITTEN
Mar 22, 2022 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED
Mar 22, 2022 GNRT F NON-FINAL ACTION E-MAILED
Mar 16, 2022 DOCK D ASSIGNED TO EXAMINER
Sep 9, 2021 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jun 29, 2021 NWAP I NEW APPLICATION ENTERED

Detailed Classifications

Class 005
Pharmaceutical products, preparations, and substances for the prevention and treatment of cancer, infectious diseases, allergies, mental illnesses, chemotherapy side effects, radiation side effects, transplantation side effects, and viral, metabolic, cardiovascular, vascular, pulmonary, blood, dermatologic, fibrotic, autoimmune, inflammatory, neurodegenerative, neuromuscular, dietary deficiency, hereditary, endocrine, eye, ear, and voice related diseases and disorders; biological products, preparations, and substances being medical preparations for the prevention and treatment of cancer, infectious diseases, allergies, mental illnesses, chemotherapy side effects, radiation side effects, transplantation side effects, and viral, metabolic, cardiovascular, vascular, pulmonary, blood, dermatologic, fibrotic, autoimmune, inflammatory, neurodegenerative, neuromuscular, dietary deficiency, hereditary, endocrine, eye, ear, and voice related diseases and disorders; immunotherapies in the nature of medical preparations for the prevention and treatment of cancer, infectious diseases, allergies, mental illnesses, chemotherapy side effects, radiation side effects, transplantation side effects, and viral, metabolic, cardiovascular, vascular, pulmonary, blood, dermatologic, fibrotic, autoimmune, inflammatory, neurodegenerative, neuromuscular, dietary deficiency, hereditary, endocrine, eye, ear, and voice related diseases and disorders; vaccines; pharmaceuticals in the nature of biotechnology platform technology, namely, viral and vaccine vectors for delivery and insertion of function-altering genetic material into human and animal patients, plants, and crops, for visualization of specific cell types, for inducing humoral and cell-mediated responses, for targeting and killing cancer cells, for removing pathological functions, for controlling biological pests, and for boosting crop yields; chemical platform technology, namely, small molecule compounds being pharmaceuticals for inducing the expression of antioxidant, anti-inflammatory, and cytoprotective proteins in non-malignant tissues, for activating the immune system, for modulating blood flow in ischemic tissues, for upregulating proinflammatory mediators in tumors, and for treating plant diseases
Class 042
Scientific and medical research and development in the fields of pharmaceuticals, biologics, agriculture, pest control, biotechnology, immunotherapies, and vaccines

Additional Information

Pseudo Mark
EPICENT RX

Classification

International Classes
005 042

USPTO Documents

Click to view cached USPTO documents for this trademark

Only administrators can request new documents from USPTO